Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers
BARCELONA — Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last year’s European …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
